In aggregate, our thorough cross-sectional and longitudinal analyses from the largest series of participants with an FTD syndrome and asymptomatic individuals with a FTD-causing mutation show that plasma NfL consistently outperforms plasma GFAP as a prognostic, susceptibility/risk, and predictive biomarker. This evidence concerns the gene GFAP and frontotemporal dementia.